Axsome Therapeutics (AXSM) Starts Phase 3 SUMMIT Trial, Is The Upside Already Priced In?

Axsome Therapeutics (AXSM) is back in focus after two linked catalysts. The first patient has been dosed in its SUMMIT Phase 3 smoking cessation trial for AXS-05, along with a mixed Q2 2026 earnings reaction.

At a share price of US$210.63, Axsome Therapeutics has seen short term momentum cool, with the 30 day share price return down 4.6% and the 90 day move down 17%, even as the year to date share price return sits at 17.9% and the 1 year total shareholder return is 69.7%. This has been supported by a much larger 3 year and 5 year total shareholder return of about 2.7x and 7.6x respectively. Recent catalysts, including the first patient dosed in the SUMMIT Phase 3 AXS-05 smoking cessation trial, a mixed Q2 2026 earnings response, and upcoming investor conference appearances, seem to be reshaping how the market weighs Axsome’s growth potential against execution and clinical risk in the near term.

Scan opportunities around Axsome Therapeutics by comparing this biotech story with a curated 17 high quality undiscovered gems that may be flying under most investors' radar.

Axsome Therapeutics now looks like a stronger CNS platform story than a few years ago, yet the share price has cooled sharply in recent months. So is that pause giving you fair value or froth?

Most Popular Narrative: 25.4% Undervalued

Against a last close of $210.63, the most followed Axsome Therapeutics narrative pegs fair value materially higher, hinging on a multi-drug CNS roll out and margin reset.

The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications), which positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.

Read the complete narrative.

Curious what has to happen for Axsome Therapeutics to support a much larger revenue line, a meaningfully higher profit margin, and a richer earnings multiple at a 7.11% discount rate? The most popular narrative spells out one detailed pathway and leans on a tight set of forecasts that you can benchmark against your own expectations.

Result: Fair Value of $282.51 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, Axsome Therapeutics faces real pressure if Auvelity or Sunosi underdeliver commercially, or if high R&D and SG&A keep net losses and dilution risk elevated.

Find out about the key risks to this Axsome Therapeutics narrative.

Next Steps

Strong opinions on Axsome Therapeutics are forming quickly, so it helps to pressure test the narrative against your own read of the numbers first. To see which potential upsides others are focusing on, review the 3 key rewards.

Looking for more Axsome Therapeutics style investment ideas?

If you want a broader watchlist beyond Axsome Therapeutics, use the Simply Wall Street Screener to spot other opportunities before they move.

• Target steady compounding by reviewing companies with resilient cash flows and strong finances through the list of solid balance sheet and fundamentals (24 results).
• Hunt for mispriced opportunities by scanning the 31 high quality undervalued stocks that combine quality fundamentals with potentially attractive entry points.
• Prioritise sleep at night holdings by focusing on the 10 resilient stocks with low risk scores that aim to keep downside risk in tighter bounds.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com